Capital, and then some
We work closely with our portfolio companies to provide not only capital, but strategic guidance and operational support. The money is the easy part; the useful part is what comes after it.
Our firm
A private equity firm built around clinical access.
We invest in the most promising early-stage companies developing transformative technologies across healthcare, biotech, and life sciences.
The Oxford Fund is a private equity firm that offers unparalleled access to deal flow sourced through our national network of physicians.
That network is the difference. Most firms see a medical technology company when it arrives at a pitch meeting, polished and already competing for attention. We tend to see it earlier — through the clinicians who are using it, or who have been asked to, and who can say plainly whether it solves a problem worth solving. Our team of experienced professionals is dedicated to identifying and supporting the companies poised to make a genuine difference in the field.
Our approach
Hands-on, by design.
At The Oxford Fund we take a hands-on approach to investing. We are not passive holders of positions — we are participants in the businesses we back.
Inception to exit
Our team has a track record of identifying and nurturing high-potential companies across the full arc of their development, and we stay involved for the length of it.
Value for every stakeholder
We are passionate about driving innovation and creating value — for founders, for clinicians, for investors, and for the patients on the other end of the technology.
Experienced team
Finance, healthcare, and technology in one room.
Our team consists of seasoned professionals with diverse backgrounds in finance, healthcare, and technology. We bring that combined experience to every investment opportunity, and we are committed to delivering exceptional results for our investors.
It is a deliberately mixed group. A promising medical device is simultaneously a clinical question, an engineering question, a regulatory question, and a capital question — and getting three of the four right is not good enough.